PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

Abstract High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is one of the most intriguing molecules in inflammatory disorders and cancers. Notably, HMGB1 is a potential therapeutic target and novel biomarker in related diseases. However, the diagnostic value of HMGB1 for benign and malignant asbestos-related diseases (ARDs) remains unclear. In this work, we detected preoperative serum HMGB1 levels in Chinese asbestos-exposed (AE) and ARDs populations and further evaluated the diagnostic value of HMGB1 in patients with certain types of ARDs, including those with pleural plaques, asbestosis, or malignant mesothelioma (MM). The experimental data presented that the serum level of HMGB1 was significantly elevated in AE and ARDs subjects. Our findings indicated that serum HMGB1 is a sensitive and specific biomarker for discriminating asbestosis- and MM-affected individuals from healthy or AE individuals. In addition, serum matrix metalloproteinases 2 and 9 are not correlated with HMGB1 in ARDs. Thus, our study provides supporting evidence for HMGB1 as a potential biomarker either for the clinical diagnosis of high-risk AE cohorts or for evaluating ARDs.
PMID
Related Publications

Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.

Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.

Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma.

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.

Authors

Mayor MeshTerms
Keywords
Journal Title disease markers
Publication Year Start




PMID- 28348451
OWN - NLM
STAT- MEDLINE
DA  - 20170328
DCOM- 20170420
LR  - 20170420
IS  - 1875-8630 (Electronic)
IS  - 0278-0240 (Linking)
VI  - 2017
DP  - 2017
TI  - Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.
PG  - 5756102
LID - 10.1155/2017/5756102 [doi]
AB  - High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is 
      one of the most intriguing molecules in inflammatory disorders and cancers.
      Notably, HMGB1 is a potential therapeutic target and novel biomarker in related
      diseases. However, the diagnostic value of HMGB1 for benign and malignant
      asbestos-related diseases (ARDs) remains unclear. In this work, we detected
      preoperative serum HMGB1 levels in Chinese asbestos-exposed (AE) and ARDs
      populations and further evaluated the diagnostic value of HMGB1 in patients with 
      certain types of ARDs, including those with pleural plaques, asbestosis, or
      malignant mesothelioma (MM). The experimental data presented that the serum level
      of HMGB1 was significantly elevated in AE and ARDs subjects. Our findings
      indicated that serum HMGB1 is a sensitive and specific biomarker for
      discriminating asbestosis- and MM-affected individuals from healthy or AE
      individuals. In addition, serum matrix metalloproteinases 2 and 9 are not
      correlated with HMGB1 in ARDs. Thus, our study provides supporting evidence for
      HMGB1 as a potential biomarker either for the clinical diagnosis of high-risk AE 
      cohorts or for evaluating ARDs.
FAU - Ying, Shibo
AU  - Ying S
AUID- ORCID: 0000-0001-5275-9383
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Jiang, Zhaoqiang
AU  - Jiang Z
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - He, Xianglei
AU  - He X
AD  - Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou,
      Zhejiang 310014, China.
FAU - Yu, Min
AU  - Yu M
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Chen, Riping
AU  - Chen R
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Chen, Junqiang
AU  - Chen J
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Ru, Guoqing
AU  - Ru G
AD  - Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou,
      Zhejiang 310014, China.
FAU - Chen, Yuan
AU  - Chen Y
AD  - Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou,
      Zhejiang 310014, China.
FAU - Chen, Wanyuan
AU  - Chen W
AD  - Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou,
      Zhejiang 310014, China.
FAU - Zhu, Lijin
AU  - Zhu L
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Li, Tao
AU  - Li T
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Zhang, Yixiao
AU  - Zhang Y
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Guo, Xinnian
AU  - Guo X
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Yin, Xianhong
AU  - Yin X
AD  - Jiading District Center for Disease Control and Prevention, Shanghai 201800,
      China.
FAU - Zhang, Xing
AU  - Zhang X
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
FAU - Lou, Jianlin
AU  - Lou J
AUID- ORCID: 0000-0002-4052-7865
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou 310013, China.
LA  - eng
PT  - Journal Article
DEP - 20170301
PL  - United States
TA  - Dis Markers
JT  - Disease markers
JID - 8604127
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HMGB1 Protein)
RN  - 0 (HMGB1 protein, human)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - Mesothelioma, Malignant
SB  - IM
MH  - Aged
MH  - Asbestosis/*blood
MH  - Biomarkers, Tumor/*blood
MH  - Case-Control Studies
MH  - Female
MH  - HMGB1 Protein/*blood
MH  - Humans
MH  - Lung Neoplasms/*blood
MH  - Male
MH  - Matrix Metalloproteinase 2/blood
MH  - Matrix Metalloproteinase 9/blood
MH  - Mesothelioma/*blood
MH  - Middle Aged
PMC - PMC5350493
COI - The authors declare that there is no conflict of interests regarding the
      publication of this paper.
EDAT- 2017/03/30 06:00
MHDA- 2017/04/21 06:00
CRDT- 2017/03/29 06:00
PHST- 2016/11/03 [received]
PHST- 2017/01/11 [revised]
PHST- 2017/01/19 [accepted]
AID - 10.1155/2017/5756102 [doi]
PST - ppublish
SO  - Dis Markers. 2017;2017:5756102. doi: 10.1155/2017/5756102. Epub 2017 Mar 1.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>